GPRA 2015
Immunization Measures

Amy V. Groom, MPH
IHS Immunization Program Manager
GPRA/GPRAMA Immunization Measures

• Childhood Immunizations
  – 4313314 coverage among children 19-35 months
  – Updated codes for FY 2015
  – Target: 73.9%

• Adult Immunizations
  – Pneumococcal vaccination among adults 65 years+
    • Pneumo vaccination on or after age 65 years (changed in FY 2014)
    • Updated codes for FY 2015
    • Target: 85.7%
  – Influenza vaccination among adults 65 years+
    • Updated codes for FY 2015
    • Target: 67.2%
Developmental Measures

• Adult Composite measure
  – Looks at age-appropriate coverage among adults 19 years and older
  – FY 2014 results: 32.9% of adults 19 years and older received all recommended vaccines

<table>
<thead>
<tr>
<th>Age Groups</th>
<th>Recommended Vaccines</th>
<th>Composite Measure Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-59 years</td>
<td>Td in last 10 years, Tdap and Influenza</td>
<td>Td/Tdap, Tdap ever, and Influenza</td>
</tr>
<tr>
<td>60-64 years</td>
<td>Td in last 10 years, Tdap, Influenza, and Zoster</td>
<td>Td/Tdap, Tdap ever, Influenza, and Zoster</td>
</tr>
<tr>
<td>65 years and older</td>
<td>Td in last 10 years, Tdap, Influenza, Zoster, and</td>
<td>Td/Tdap, Tdap ever, Influenza, Zoster, and Pneumococcal Polysaccharide Vaccine, 23 Valent (PPSV23)</td>
</tr>
<tr>
<td></td>
<td>Pneumococcal Polysaccharide Vaccine, 23 Valent (PPSV23)</td>
<td></td>
</tr>
<tr>
<td>All Ages</td>
<td>All age-appropriate vaccines</td>
<td>Proportion of adults who received all vaccines recommended for their age group</td>
</tr>
</tbody>
</table>

• Pneumococcal vaccine for adults 65+ years
  – Developmental measure to exclude pneumococcal conjugate vaccine codes for this measure

• Childhood 4313313 measure
  – Looks at 3 pneumococcal conjugate rather than 4
  – Developed in the event ACIP decides to routinely recommend 3 rather than 4 doses of PCV13. No decision has yet been made.
The PCV13 Conundrum

• 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) is currently recommended for all adults 65 years and older

• In August 2014, the Advisory Committee on Immunization Practices voted to ALSO routinely recommend the 13-valent pneumococcal conjugate vaccine (PCV13) for ALL adults 65 years and older

• TIME LIMITED recommendation
  – To be re-visited in 2018
Issues

• Adults 65 years and older recommended to receive BOTH PCV13 and PPSV23

• In patients not previously vaccinated with PPSV23
  – Should receive PCV13 first
  – Recommended interval between PCV13 and PPSV23 is 6 months to 1 year

• Patients who have received PPSV23 on or after age 65 years
  – Should receive dose of PCV13 at least 1 year after PPSV23
PCV13 – Impact on current GPRA Measure

- Current GPRA Pneumococcal logic counts PCV13 as a dose of PPSV23 for the purposes of the GPRA Pneumococcal measure
  - Prior to the 2014 PCV13 recommendation, these likely represented miscodes for PPSV23
  - With new recommendation, more adults likely to receive PCV13
  - Inclusion of PCV13 codes may result in over-estimate of true PPSV23 coverage
  - Exclusion of PCV13 codes would, however, unfairly “ding” sites who follow the recommendation, as there is a 6 – 12 month recommended interval required between PCV13 and PPSV23
GPRA Pneumococcal Logic

• Because PCV13 for adults 65 years and older is a time-limited recommendation, we will NOT update current GPRA logic to reflect changes.
• GPRA logic will continue to count PCV13 codes as valid for meeting the PPSV23 requirement.
• This may result in an over-estimate of current PPSV23 coverage.